Fujita, Hideki http://orcid.org/0000-0001-8657-0618
Gooderham, Melinda http://orcid.org/0000-0001-8926-0113
Romiti, Ricardo http://orcid.org/0000-0003-0165-3831
Funding for this research was provided by:
Boehringer Ingelheim (The medical writing was funded by Boehringer Ingelheim)
Article History
Accepted: 28 October 2021
First Online: 21 January 2022
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.
: Medical writing support was funded by Boehringer Ingelheim.
: Hideki Fujita has received honoraria or fees for serving on advisory boards, as a speaker, and as a consultant, as well as grants as an investigator from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Chugai Pharmaceutical, Esai, Eli Lilly, Janssen, Japan Blood Products Organization, JMEC, Kaken, Kyorin, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nihon Pharmaceutical, Novartis, Sanofi, Sun Pharma, Taiho, Torii, UCB, and Ushio. Melinda Gooderham has been an investigator, speaker, and/or advisor for AbbVie, Amgen, Akros, Arcutis, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, UCB, and Bausch. Ricardo Romiti has served as a scientific consultant, speaker, or clinical study investigator for AbbVie, Boehringer Ingelheim, Galderma, Janssen-Cilag, Eli-Lilly, LEO Pharma, Novartis, Pfizer, TEVA, and UCB.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors, who provided guidance to OPEN Health Communications on the content of the article, critically revised the work, and approved the content for publication.